

DAFTAR PUSTAKA

1. Zou et al. Lipids in Health and Disease. LDL/HDL cholesterol ratio is associated with new-onset NAFLD in Chinese non-obese people with normal lipids: a 5-year longitudinal cohort study. (2021) 20:28
2. Wang XJ, Malhi H. Nonalcoholic fatty liver disease. Ann Intern Med. 2018; 169: ITC65–80.
3. Younossi ZM. Non-alcoholic fatty liver disease - a global public health perspective. J Hepatol. 2019;70:531–44.
4. Wattacheril J. Extrahepatic manifestations of nonalcoholic fatty liver disease. Gastroenterol Clin N Am. 2020;49:141–9
5. Guo et al. Lipids in Health and Disease. The triglyceride-glucose index is associated with the severity of hepatic steatosis and the presence of liver fibrosis in nonalcoholic fatty liver disease: a cross-sectional study in Chinese adults. (2020) 19:218
6. Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11–20.
7. Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016;65(8):1038–48.
8. Samuel VT, Shulman GI. Nonalcoholic Fatty Liver Disease, Insulin Resistance, and Ceramides. N Engl J Med. 2019;381(19):1866–9.



MC Endocrine Disorders. Association between triglyceride–glucose index and
lic fatty liver disease in type 2 diabetes mellitus. (2022) 22:261

10. Mota M, Banini BA, Cazanave SC, Sanyal AJ. Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease. *Metabolism*. 2016;65:1049–61.
11. Ran Li et al. Correlation of multiple lipid and lipoprotein ratios with nonalcoholic fatty liver disease in patients with newly diagnosed type 2 diabetic mellitus: A retrospective study. DOI 10.3389/fendo.2023.1127134
12. Ren XY, Shi D, Ding J, Cheng ZY, Li HY, Li JS, et al. Total cholesterol to highdensity lipoprotein cholesterol ratio is a significant predictor of nonalcoholic fatty liver: Jinchang cohort study. *Lipids Health Dis* (2019) 18:47. doi: 10.1186/s12944-019-0984-9
13. Zhang M, Zhou J, Liu Y, Sun X, Luo X, Han C, et al. Risk of type 2 diabetes mellitus associated with plasma lipid levels: The rural Chinese cohort study. *Diabetes Res ClinPract* (2018) 135:150–7. doi: 10.1016/j.diabres.2017.11.011
14. Fan et al. Lipids in Health and Disease. Triglycerides to high-density lipoprotein cholesterol ratio as a surrogate for nonalcoholic fatty liver disease: a crosssectional study (2019) 18:39
15. Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. *AASLD Practice Guidance on the Clinical Assessment and Management of Nonalcoholic Fatty Liver Disease*. *Hepatology* 77(5):p 1797-1835, May 2023
16. Dowman JK, Tomlinson JW, Newsome PN. Pathogenesis of non-alcoholic fatty liver disease. *Q J Med* 2010; 103:71–83
17. Postic C, Girard J. Contribution of de novo fatty acid synthesis to hepatic steatosis and instance: lessons from genetically engineered mice. *J Clin Invest* 2008; 118:829–



18. Targher G, Bertolini L, Padovani R, Rodella S, Tessari R, Zenari L, et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. *Diabetes Care* 2007; 30:1212–8.
19. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American association for the study of liver diseases. *Hepatology (Baltimore Md)* (2018) 67:328–57.
20. Castera L, Friedrich-Rust M, Loomba R. Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. *Gastroenterology* (2019) 156:1264–81.e4.
21. Sudoyo A, Simadibrata M, Setiyohadi B, Syam AF, eds. *Buku Ajar Ilmu Penyakit Dalam* . VI. Pusat Penerbitan Departemen Ilmu Penyakit Dalam FKUI; 2014:1772. Published online 2014:2014.
22. Sporea I, Şirli R, Başa E, et al. The value of transabdominal ultrasound for assessment of the severity of liver steatosis as compared to liver biopsy. *Cent Eur J Med*. 2009;4(4):490-495.
23. McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM. Evidence of NAFLD progression from steatosis to fibrosing steatohepatitis using paired biopsies: implications for prognosis and clinical management. *J Hepatol*. 2015;62:1148–55.
24. Kwok R, Choi KC, Wong GL, Zhang Y, Chan HL, Luk AO, et al. Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver measurements: a prospective cohort study. *Gut*. 2016;65: 1359–68.



25. Bazick J, Donithan M, Neuschwander-Tetri BA, Kleiner D, Brunt EM, Wilson L, et al. Clinical model for NASH and advanced fibrosis in adult patients with diabetes and NAFLD: guidelines for referral in NAFLD. *Diabetes Care*. 2015;38: 1347–55
26. Lonardo A, Bellentani S, Argo CK, Ballestri S, Byrne CD, Caldwell SH, et al. Epidemiological modifiers of non-alcoholic fatty liver disease: focus on high-risk groups. *Dig Liver Dis*. 2015;47:997–1006
27. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. *Aliment Pharmacol Ther*. 2011;34:274–85.
28. Ciardullo S, Monti T, Perseghin G. High prevalence of advanced liver fibrosis assessed by transient elastography among U.S. adults with type 2 diabetes. *Diabetes Care*. 2021; 44:519–25
29. Alizargar J, Bai CH, Hsieh NC, Wu SV. Use of the triglyceride-glucose index (TyG) in cardiovascular disease patients. *Cardiovasc Diabetol*. 2020;19:8. 13.
30. Bullon-Vela V, Abete I, Tur JA, Konieczna J, Romaguera D, Pinto X, Corbella E, Martinez-Gonzalez MA, Sayon-Orea C, Toledo E, et al. Relationship of visceral adipose tissue with surrogate insulin resistance and liver markers in individuals with metabolic syndrome chronic complications. *Ther Adv Endocrinol Metab*. 2020;11:2042018820958298.



, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty disease (NAFLD). *Metabolism* (2016) 65:1038–48. doi:

metabol.2015.12.012

32. Amor AJ, Perea V. Dyslipidemia in nonalcoholic fatty liver disease. *Curr Opin Endocrinol Diabetes Obes.* 2019;26:103–8.
33. Zhang XX, Wei M, Shang LX, Lu YM, Zhang L, Li YD, et al. LDL-C/HDL-C is associated with ischaemic stroke in patients with non-valvular atrial fibrillation: a case-control study. *Lipids Health Dis.* 2020;19:217.
34. Liu L, Yin P, Lu C, Li J, Zang Z, Liu Y, et al. Association of LDL-C/HDL-C ratio with stroke outcomes within 1 year after onset: a hospital-based follow-up study. *Front Neurol.* 2020;11:408.
35. Kawamoto R, Tabara Y, Kohara K, Miki T, Kusunoki T, Takayama S, et al. Lowdensity lipoprotein cholesterol to high-density lipoprotein cholesterol ratio is the best surrogate marker for insulin resistance in non-obese Japanese adults. *Lipids Health Dis.* 2010;9:138.
36. Manne V, Handa P, Kowdley KV. Pathophysiology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. *Clin Liver Dis.* 2018;22:23–37.
37. Ling Q, Chen J, Liu X, Xu Y, Ma J, Yu P, Zheng K, Liu F, Luo J. The triglyceride and glucose index and risk of nonalcoholic fatty liver disease: A dose-response meta-analysis. *Front Endocrinol (Lausanne).* 2023 Jan 19;13:1043169.
38. Guerrero-Romero F, Simental-Mendía LE, González-Ortiz M, Martínez-Abundis E, Ramos-Zavala MG, Hernández-González SO, et al. The product of triglycerides and glucose, a simple measure of insulin sensitivity. Comparison euglycemic-hyperinsulinemic *lin Endocrinol Metab* (2010) 95:3347–51.
- man, Dewi Resnawita, Haerani Rasyid, Hasyim Kasim, Syakib Bakri, Husaini man AS. Daud, Arifin Seweng. The concordance of triglyceride glucose index



(TyG index) and homeostatic model assessment for insulin resistance (Homa-IR) in non-diabetic subjects of adult Indonesian males. *Clinical Epidemiology and Global Health* Volume 9. 2021 ; 227-230

40. Wang J, Li H, Wang X, Shi R, Hu J, Zeng X, Luo H, Yang P, Luo H, Cao Y, Cai X, Chen S, Wang D. Association between triglyceride to high-density lipoprotein cholesterol ratio and nonalcoholic fatty liver disease and liver fibrosis in American adults: an observational study from the National Health and Nutrition Examination Survey 2017-2020. *Front Endocrinol (Lausanne)*. 2024 Jul 16;15:1362396.
41. Fukuda Y, Hashimoto Y, Hamaguchi M, Fukuda T, Nakamura N, Ohbora A, Kato T, Kojima T, Fukui M. Triglycerides to high-density lipoprotein cholesterol ratio is an independent predictor of incident fatty liver; a population-based cohort study. *Liver Int*. 2016 May;36(5):713-20.
42. Li Y, Zheng R, Li J, Feng S, Wang L, Huang Z. Association between triglyceride glucose-body mass index and non-alcoholic fatty liver disease in the non-obese Chinese population with normal blood lipid levels: a secondary analysis based on a prospective cohort study. *Lipids Health Dis*. 2020;19:229.
43. Kyung-Soo Kim, You Cheol Hwang, Hong-Yup Ahn, Sung-Woo Park, Cheol-Young Park; 1596-P: Triglyceride and Glucose (TyG) Index Is an Effective Predictor of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis. *Diabetes* 1 June 2019; 68 (Supplement_1): 1596-P

